ASGCT Annual Meeting 2026: Live Event Coverage and Key Insights

ASGCT Annual Meeting 2026: Live Event Coverage and Key Insights

The ASGCT Annual Meeting 2026 is set to be the premier event for cell and gene therapy professionals. This live coverage will bring you the most significant advancements and industry insights from Boston, where over 2,100 abstracts and high-level symposia will shape the commercial trajectory of gene editing, CAR-T, and AAV therapies.

Key Takeaways

• Who should attend: Business development teams, R&D leaders, and investors tracking the cell and gene therapy pipeline. The meeting is the largest and most comprehensive CGT event of the year, with over 2,100 pieces of original research now live in the abstracts collection. As of early 2026, the FDA has approved more than 20 cell and gene therapy products, and the number of active clinical trials exceeds 4,000, according to ClinicalTrials.gov.
• Catalyst watch: High-level symposia featuring speakers who have redefined the boundaries of the field will run from May 11–15. Virtual attendance is available for those who cannot travel to Boston. The program and workshops include sessions on in vivo gene editing, allogeneic cell therapies, and manufacturing scalability. Watch for updated readouts from ongoing pivotal trials that could shift competitive landscapes.
• Timelines to note: Registration for the ASGCT 2027 Annual Meeting opens in December 2026. The ASGCT Events app is now live for navigating sessions, abstracts, and exhibitor booths in real time. Companies presenting first-in-human data could see immediate stock moves; the app allows attendees to set alerts for oral presentations.

What is on the agenda?

The ASGCT 2026 Annual Meeting kicks off May 11 in Boston with a scientific program anchored by high-level symposia. Organizers describe it as the largest and most comprehensive cell and gene therapy event, and this year’s abstract count backs that up: more than 2,100 submissions cover everything from base editing and prime editing to next-generation viral vectors and CAR-T durability. The symposia will feature keynote presentations from academic pioneers and industry executives who have pushed products into the clinic and onto the market. Parallel workshop tracks dive into regulatory pathways, AAV immunogenicity, and lentiviral manufacturing bottlenecks. For remote teams, the virtual attendance option provides live-streamed sessions and on-demand access for 30 days after the meeting.

The breadth of research reflects a field that has matured dramatically. According to the FDA’s list of approved cellular and gene therapy products, the agency has now cleared more than 20 such therapies, including landmark approvals for sickle cell disease and hemophilia B. The ASGCT program includes dedicated sessions on how these approved products have performed in the real world and what durability data look like two to four years post-market. In parallel, sessions on EMA’s advanced therapy framework will examine how regulators on both sides of the Atlantic are aligning on accelerated approval pathways.

Which companies should investors watch?

Investors should start by scanning the full abstract collection, which went live ahead of the meeting and includes clinical-stage data from dozens of biotechs. While we cannot preview individual trial results here, the sheer volume of over 2,100 abstracts means that several companies will unveil first-in-human data or updated efficacy and safety reads. The symposia program highlights speakers who have redefined boundaries in the field — often the same names behind public companies or platforms that have attracted major partnerships. Look for presentations on in vivo gene editing platforms, allogeneic CAR-T programs aiming to lower cost and expand access, and AAV-based therapies for CNS and rare diseases. The ASGCT Events app, available on the App Store, allows attendees to bookmark specific abstracts and set alerts for oral presentations that could move stock prices.

Notable themes this year include the push toward non-viral delivery systems. Several companies are presenting data on lipid nanoparticles for extrahepatic targeting, which could broaden the therapeutic scope of gene editing beyond the liver. Another hot area is in vivo CAR-T generation — using vectors to program T cells directly in the body, potentially eliminating the complex ex vivo manufacturing steps that have limited access to CAR-T therapies today. Investors should also watch for updates on durability from the first wave of approved gene therapies, as waning efficacy has been a concern in hemophilia and certain metabolic diseases. The FDA’s approved products list shows that several early approvals are now approaching multi-year follow-up; any signs of stable or improving transgene expression would be a bullish signal for the entire field.

How are regulators shaping the gene therapy pipeline?

Regulatory clarity remains a top concern for developers. At ASGCT 2026, FDA and EMA representatives are scheduled for joint sessions on dose-finding for AAVs, immunogenicity testing standards, and post-approval monitoring requirements. The FDA has published updated guidance on long-term follow-up for gene therapy recipients, and the meeting will include a workshop dedicated to risk-based monitoring strategies. For companies planning global trials, alignment between the FDA and EMA on clinical endpoints is critical — especially for rare diseases where single-arm registrational studies are common. The EMA’s advanced therapy medicinal products (ATMP) framework has undergone revisions to streamline qualification, and ASGCT provides a venue for developers to engage directly with regulators on these changes.

Manufacturing scalability also takes center stage. With several approved products now facing supply constraints, the meeting will feature data on closed-system bioreactors, novel purification methods, and potency assays that correlate with clinical outcomes. A panel on “CGT manufacturing 2030” will explore how the industry can reduce cost of goods by an order of magnitude, potentially unlocking larger patient populations beyond ultra-rare diseases.

Frequently Asked Questions